Please assess the completion status of the following clinical trial:

Trial Title: TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Histopathologically-confirmed, well-differentiated metastatic neuroendocrine tumor~* Documented history of carcinoid syndrome and currently experiencing ≥4 bowel movements per day during the Run-in period~* Currently receiving stable-dose somatostatin analog (SSA) therapy~* Minimum dose of long-acting release (LAR) or depot SSA therapy~  * Octreotide LAR at 30 mg every 4 weeks~ * Lanreotide Depot at 120 mg every 4 weeks~ * Patients who cannot tolerate SSA therapy at a level indicated above will be allowed to enter at their highest tolerated dose~* Ability and willingness to provide written informed consent~Exclusion Criteria:~* Presence of diarrhea attributed to any condition(s) other than carcinoid syndrome~* Karnofsky Performance status ≤60%~* Treatment with any tumor directed therapy, including interferon, chemotherapy, mechanistic target of rapamycin (mTOR) inhibitors \<4 weeks prior to Screening, or hepatic embolization, radiotherapy, radiolabelled SSA, and/or tumor debulking \<12 weeks prior to Screening~* History of short bowel syndrome (SBS)~* Clinically significant cardiac arrhythmia, bradycardia, tachycardia that would compromise patient safety or the outcome of the study~* Previous exposure to telotristat etiprate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 250 mg Telotristat Etiprate (Type: EXPERIMENTAL): Following a 3 to 4-week run-in period on stable-dose somatostatin analog (SSA) therapy (octreotide or lanreotide) participants were randomized to receive one 250 mg telotristat etiprate tablet plus one placebo-matching telotristat etiprate tablet administered three times daily for 12 Weeks in the double-blind treatment period, followed by a 36 week open-label extension period.
- 500 mg Telotristat Etiprate (Type: EXPERIMENTAL): Following a 3 to 4-week run-in period on stable-dose SSA therapy (octreotide or lanreotide) participants were randomized to receive, one telotristat etiprate 250 mg plus one placebo-matching telotristat etiprate tablet administered 3 times daily for 1 week, followed by two telotristat etiprate (250 mg) tablets administered three times daily for 11 weeks in the double-blind treatment period, followed by a 36 week open-label extension period.
- Placebo (Type: PLACEBO_COMPARATOR): Following a 3 to 4-week run-in period on stable-dose SSA therapy (octreotide or lanreotide) participants were randomized to receive two placebo-matching telotristat etiprate tablets administered three times daily for 12 weeks in the double-blind treatment period, followed by a 36 week open-label extension period.
- Telotristat Etiprate Open-Label Extension (Type: EXPERIMENTAL): Patients previously assigned to 250 mg or 500 mg three times daily of telotristat etiprate were administered two 250 mg telotristat etiprate tablets three times daily in a 36 week open-label extension (OLE) period. Patients previously assigned to placebo were administered one 250 mg telotristat etiprate tablet plus one placebo-matching tablet three times daily for one week, followed by two 250 mg telotristat etiprate tablets three times daily for 35 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).